Loading clinical trials...
Loading clinical trials...
A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours
Conditions
Interventions
FP-1305 (bexmarilimab)
Locations
11
United States
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Clinical Research Institute HUCH Ltd
Helsinki, Finland
Oulu University Hospital
Oulu, Finland
Tampere University Hospital
Tampere, Finland
Turku University Hospital
Turku, Finland
The Institut Gustave Roussy
Villejuif, France
Start Date
December 3, 2018
Primary Completion Date
September 6, 2023
Completion Date
October 31, 2023
Last Updated
April 2, 2025
NCT04550494
NCT05053971
NCT03375307
NCT00026884
NCT05039801
NCT05198830
Lead Sponsor
Faron Pharmaceuticals Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions